Drug Trial Radar · NCT00251693
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Last checked: Nov 20, 2026Latest source record: Feb 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,038
Actual
Start
Dec 2005
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
Conditions
- Esophagitis, Reflux
- Esophagitis, Peptic
Interventions
Dexlansoprazole MRDrug
Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
Dexlansoprazole MRDrug
Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
LansoprazoleDrug
Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.Time frame: 8 Weeks
- Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.Time frame: 8 weeks
Locations
140 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Alabaster, Alabama
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Anaheim, California
Site not named
Chula Vista, California
Site not named
Fullerton, California
Site not named
Garden Grove, California
Site not named
Irvine, California
Site not named
Lancaster, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Mission Hills, California
Site not named
Palm Springs, California
Site not named
Pasadena, California
Site not named
Redwood City, California
Site not named
San Diego, California
Site not named
San Luis Obispo, California
Site not named
Boulder, Colorado
Site not named
Colorado Springs, Colorado
Site not named
Lone Tree, Colorado
Site not named
Wheat Ridge, Colorado
Site not named
Waterbury, Connecticut
Site not named
Boynton Beach, Florida
Site not named
Jacksonsville, Florida
Site not named
Jupiter, Florida
Site not named
Kissimmee, Florida
Site not named
Lakeland, Florida
Site not named
New Port Richey, Florida
Site not named
Atlanta, Georgia
Site not named
Honolulu, Hawaii
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Hines, Illinois
Site not named
Oak Park, Illinois
Site not named
Rockford, Illinois
Site not named
Clive, Iowa
Site not named
Dubuque, Iowa
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.